Genprex, Inc. (GNPX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GNPX Stock Price Chart Interactive Chart >
GNPX Price/Volume Stats
| Current price | $1.34 | 52-week high | $2.67 |
| Prev. close | $1.31 | 52-week low | $0.97 |
| Day low | $1.31 | Volume | 94,417 |
| Day high | $1.37 | Avg. volume | 302,339 |
| 50-day MA | $1.29 | Dividend yield | N/A |
| 200-day MA | $1.46 | Market Cap | 64.35M |
Genprex, Inc. (GNPX) Company Bio
Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas.
Latest GNPX News From Around the Web
Below are the latest news stories about GENPREX INC that investors may wish to consider to help them evaluate GNPX as an investment opportunity.
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of PittsburghTechnologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes AUSTIN, Texas, Jan. 5, 2023 /PRNewswire/ -- Genprex, Inc…. |
Genprex Inc. Shares Are Up 21.37% Since The Beginning Of The YearGenprex Inc. (NASDAQ:GNPX) has a beta value of -0.32 and has seen 0.6 million shares traded in the recent trading session. The company, currently valued at $65.79M, closed the recent trade at $1.79 per share which meant it gained $0.2 on the day or 12.58% during that session. The GNPX stock price is -75.42% off … Genprex Inc. Shares Are Up 21.37% Since The Beginning Of The Year Read More » |
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for DiabetesGenprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22- |
Do investors need to be concerned about Genprex Inc. (GNPX)?In Friday’s session, Genprex Inc. (NASDAQ:GNPX) marked $1.45 per share, up from $1.25 in the previous session. While Genprex Inc. has overperformed by 16.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GNPX rose by 11.54%, with highs and lows ranging from $3.62 to $0.97, whereas […] |
After Genprex Inc. (NASDAQ: GNPX) Surges -451.72% From Highs, What Will It Look Like?During the last session, Genprex Inc. (NASDAQ:GNPX)’s traded shares were 0.3 million, with the beta value of the company hitting -0.27. At the end of the trading day, the stock’s price was $1.45, reflecting an intraday gain of 16.00% or $0.2. The 52-week high for the GNPX share is $3.62, that puts it down -149.66 … After Genprex Inc. (NASDAQ: GNPX) Surges -451.72% From Highs, What Will It Look Like? Read More » |
GNPX Price Returns
| 1-mo | 12.61% |
| 3-mo | -4.96% |
| 6-mo | -3.60% |
| 1-year | -27.57% |
| 3-year | 4.69% |
| 5-year | N/A |
| YTD | -7.59% |
| 2022 | 10.69% |
| 2021 | -68.43% |
| 2020 | 1,196.88% |
| 2019 | -70.91% |
| 2018 | N/A |
Loading social stream, please wait...